Posttransplant outcomes
| . | MMUD (N = 72) . | MUD (N = 193) . |
|---|---|---|
| Alive | 37 (51) | 87 (45) |
| Median follow-up (range), y | 3.5 (1.0-10.1) | 4.3 (0.8-12.5) |
| Alive without relapse | 30 (42) | 58 (30) |
| Off immunosuppression | 22 (31) | 65 (34) |
| Alive without GVHD or relapse | 15 (21) | 32 (17) |
| Alive with relapse or disease progression | 7 (10) | 29 (15) |
| Median time to progression (range), y | 0.8 (0.3-2.1) | 1.3 (0.1-12.0) |
| Deceased | 35 (49) | 106 (55) |
| Death from relapse or disease progression | 22 (31) | 75 (39) |
| Death from other cause | 13 (18) | 31 (16) |
| Acute GVHD | 4 (6) | 4 (2) |
| Chronic GVHD | 4 (6) | 8 (4) |
| Infection | 2 (3) | 8 (4) |
| Secondary malignancy* | 2 (3) | 3 (2) |
| Other causes of death† | 1 (1) | 8 (4) |
| . | MMUD (N = 72) . | MUD (N = 193) . |
|---|---|---|
| Alive | 37 (51) | 87 (45) |
| Median follow-up (range), y | 3.5 (1.0-10.1) | 4.3 (0.8-12.5) |
| Alive without relapse | 30 (42) | 58 (30) |
| Off immunosuppression | 22 (31) | 65 (34) |
| Alive without GVHD or relapse | 15 (21) | 32 (17) |
| Alive with relapse or disease progression | 7 (10) | 29 (15) |
| Median time to progression (range), y | 0.8 (0.3-2.1) | 1.3 (0.1-12.0) |
| Deceased | 35 (49) | 106 (55) |
| Death from relapse or disease progression | 22 (31) | 75 (39) |
| Death from other cause | 13 (18) | 31 (16) |
| Acute GVHD | 4 (6) | 4 (2) |
| Chronic GVHD | 4 (6) | 8 (4) |
| Infection | 2 (3) | 8 (4) |
| Secondary malignancy* | 2 (3) | 3 (2) |
| Other causes of death† | 1 (1) | 8 (4) |
Data are presented as n (%) unless otherwise indicated.
Secondary malignancies include donor-derived myelodysplastic syndrome, diffuse large B-cell lymphoma, gastric adenocarcinoma, rectal adenocarcinoma, and thoracic sarcoma.
Other causes of death include pulmonary embolism, cerebrovascular accident, cardiac arrest, thrombotic thrombocytopenic purpura, and suicide.